SOURCE: NeoStem, Inc.

January 25, 2008 08:47 ET

NeoStem Honored as a Leading Biotechnology Company in Southern Nevada at the Henderson Ninth Annual Economic Development Awards

NEW YORK, NY--(Marketwire - January 25, 2008) - NeoStem, Inc. (AMEX: NBS), a leading developer of adult stem cell technologies, was honored as a leading biotechnology company at the Henderson Ninth Annual Economic Development Awards on January 24th. The award comes just months after the expansion of NeoStem's adult stem cell collection center network into Henderson, Nevada. NeoStem's proprietary procedures and technology enable the collection and storage of an individual's own adult stem cells as a safeguard in the event the stem cells are needed by the individual for future medical use.

"The City of Henderson's support of NeoStem is another important building block as we work to expand our network of adult stem cell collection centers throughout the nation," remarked Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "The National Institutes of Health lists more than 1,500 clinical trials currently underway in the US investigating adult stem cell use as a potential breakthrough therapy for numerous diseases and medical conditions and we are committed to making our technology widely available in anticipation of many of these therapies one day becoming standard treatments."

The ability of people to readily harvest and store their own stem cells is the back bone of the fast growing area of regenerative medicine. Adult stem cell therapy has been used for many years in treating over 40 diseases including bone marrow cancers, such as leukemia, lymphomas and multiple myelomas. Other diseases such as radiation sickness and bone marrow deficiencies from chemotherapy have successfully been treated as well. Among the diseases and medical conditions being investigated in the multitude of clinical trials underway are cancer, diabetes, heart and vascular disease and autoimmune disorders such as lupus, multiple sclerosis, arthritis, and other conditions.

"Biotechnology is an important business development for Southern Nevada as we continue to grow. Through its network of collection centers, NeoStem offers a valuable service to the residents of Henderson in many respects. We look forward to continuing to assist NeoStem in its growth within Southern Nevada," commented Bob Cooper, Economic Development Manager, The City of Henderson.

About NeoStem

NeoStem is a biotechnology company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. Although adult stem cell therapies are generally not standard of care, the Company believes medicine is on the threshold of a plethora of such new therapies. NeoStem recently acquired the exclusive rights to a technology developed by researchers at the University of Louisville involving Very Small Embryonic-Like (VSEL) Stem Cells shown to have several physical characteristics of embryonic stem cells, which can be harvested from the peripheral blood, grown in the laboratory and multiplied into clusters of cells that can differentiate into specialized cells found in substantially all the different types of cells and tissue that make up the body. For more information, please visit:

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, to develop the VSEL technology, the future of regenerative medicine and the role of adult stem cells and VSELs in that future, the future use of adult stem cells and VSELs as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangements to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company's current or future patent applications result in issued patents; and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at under "Search for Company Filings."

Contact Information